Arcutis Biotherapeutics【ARQT】銘柄情報

Arcutis Biotherapeutics Inc (ARQT) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

25.9755

( 1.55% )

買値

25.54

売値

25.75

出来高

1,537,177

25.09 日の範囲 25.83

12.97 52 週間の範囲 31.77

時価総額

3.249B

前日終値

25.58

始値

25.67

時刻

25.9696

最終取引時間

財務取引量

US$ 39,170,031

VWAP

25.4818

平均取引量 (3 か月)

US$ 1,593,200

発行済株式数

125,083,374

配当利回り

PER

-1.31k

1 株当たり利益 (EPS)

-0.02

歳入

415.62M

純利益

-2.38M

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam se... Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.arcutis.com

本社

Westlake Village, United States

設立

2026

Arcutis Biotherapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ARQT. The last closing price for Arcutis Biotherapeutics was US$25.58. Over the last year, Arcutis Biotherapeutics shares have traded in a share price range of US$ 12.97 to US$ 31.77.

Arcutis Biotherapeutics currently has 125,083,374 shares in issue. The market capitalisation of Arcutis Biotherapeutics is US$3.25 billion. Arcutis Biotherapeutics has a price to earnings ratio (PE ratio) of -1,314.14.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including...

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	4.0755	18.6095890411	21.9	25.9755	21.72	1811606	24.19003996	CS
4	5.9555	29.7477522478	20.02	25.9755	19.295	1771925	21.74456325	CS
12	3.8855	17.5894069715	22.09	25.9755	19.295	1561919	22.19402546	CS
26	-2.6645	-9.30342178771	28.64	30.75	19.295	1549888	24.4664327	CS
52	12.3555	90.7158590308	13.62	31.77	12.97	1803612	22.10926543	CS
156	15.5855	150.00481232	10.39	31.77	1.76	2446748	11.91299164	CS
260	-2.6245	-9.17657342657	28.6	31.77	1.76	1683751	12.53944371	CS